VANCOUVER, BRITISH COLUMBIA - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company focused on developing therapies for difficult-to-treat cancers, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the board effective immediately, and the board has formally appointed Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, as a director. This appointment is made pursuant to the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
These changes are designed to ensure that the board continues to meet Helix's evolving governance and capital markets requirements and has the composition and experience needed to support the company's clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in future endeavors.
Helix BioPharma is a clinical-stage oncology company dedicated to developing therapies for underserved patient populations with difficult-to-treat cancers. The company's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
The board's restructuring comes at a pivotal time as Helix advances its clinical programs and seeks to strengthen its position in the oncology space. By appointing Dr. Mehrling, who has been leading the company's strategic direction, the board ensures alignment between management and governance. This move is expected to streamline decision-making processes and reinforce the company's commitment to its pipeline development.
Helix BioPharma's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). The company continues to focus on advancing its innovative therapies, which have the potential to address significant unmet medical needs in oncology.
For more information about Helix BioPharma and its pipeline, visit https://www.helixbiopharma.com/. Details regarding the strategic acquisition from the Laevoroc Group can be found at https://www.helixbiopharma.com/fy2025/helix-biopharma-secures-pre-ind-candidates-leumuna-and-gemceda-in-strategic-acquisition-from-the-laevoroc-group/.
